Sign up
Pharma Capital

Motif Bio secures new patents around optimal dose for iclaprim out to 2037

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) discusses with Proactive Investors the granting of two US patents which pushes their exclusivity over the antibiotic iclaprim out to 2037.

Having successfully negotiated two Phase III clinical trials, Motif is gearing up to take its next-generation antibiotic to market.


View full MTFB profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.